Authors : A.G. Nerkar, A.G. Nerkar
DOI : 10.18231/j.ctppc.2022.013
Volume : 4
Issue : 2
Year : 2022
Page No : 67-74
Growth factors receptors and hormones play an important role several cell minor cell types.With advent of advancement in Breast cancer (BC) treatment and therapies ther of there has been major advancement in this area after this discovery. The combined sciences of cellular biology and therapeutic fields have made the breast cancer a seized cure area for discoveries of new therapies and its design including the heterogeneity. This article reviews the numerous prospective innovative therapies for targeting major cell subtypes of BC cells, as well as the present therapeutic regimens. In the personalised BC drug, speedy scientific advancement of poly inhibitors (ADP-ribose) polymerase, cyclin-dependent kinases four and six, phosphatidylinositol 3-kinase / protein kinase b / mammalian target rapamycin pathway, histone deacetylation, multi-concentrated in tyrosine kinases, as well as antibodies. The Triple negative breast cancer (TNBC) has been the most challenging area for design of therapies and for drug discovery. For TNBC, as such there is no approved treatment and it is most dangerous type of BC. The article also discusses the TNBC heterogeneity and TNBC molecular subtyping. It could also help find medications to treat this terrible disease. The cell proliferation and propagation inhibitors for treatment-resistant strains also puts the invention of targets for small molecules of BC in concern.
Keywords: Breast cancer, Inhibitors of cyclin-dependent kinases 4 and 6, Hormone receptor, Human epidermal growth factor receptor 2, Poly (ADP-ribose) polymerase inhibitor